title: [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
abstract: OBJECTIVE
  To investigate the clinical value of tumor markers CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of patients with gastric cancer.
  
  
  METHODS
  One hundred and sixty gastric cancer patients who had received treatment from 2002 to 2007 at the Beijing Cancer Hospital were retrospectively analyzed. Blood samples were taken from patients upon admission to the hospital, and CEA, CA19-9, CA72-4, CA242 levels were detected. Statistical analysis was performed to identify the clinical value of these tumor markers in diagnosis and prognosis.
  
  
  RESULTS
  On initial diagnosis, the positive rates of CEA, CA19-9, CA72-4 and CA242 were 37.7%, 26.7%, 37.6% and 21.3%, respectively, and the positive rate of combined detection was 62.9%. CEA was more frequently positive in patients with lymph node metastasis (P=0.029); CA72-4 was more frequently positive in patients with vascular involvement and advanced stage (P=0.039, P=0.011). Multivaraite analysis showed that CA72-4 was an independent prognostic factor (P=0.012). Patients with positive CA72-4 carried a 2.147-fold increased risk of death than those with negative CA72-4. Kaplan-Meier analysis showed that patients with positive CA19-9 or positive CA72-4 had worse survival than those with negative CA19-9 or CA72-4 (P=0.006, P=0.002).
  
  
  CONCLUSIONS
  Tumor markers including CEA, CA19-9, CA72-4 and CA242 have clinical significance and prognostic value in patients with gastric cancer. Combined detection of four tumor markers can increase the positive rate. CA72-4 is an independent prognostic factor. CA19-9 and CA72-4 are associated with the prognosis of patients with gastric cancer.
authors.affiliation: Department of Gastrointestinal Cancer Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Yu-bing
authors.initials: YB
authors.lastname: Zhu
authors.forename: Shao-hua
authors.initials: SH
authors.lastname: Ge
authors.forename: Lian-hai
authors.initials: LH
authors.lastname: Zhang
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Wang
authors.forename: Xiao-fang
authors.initials: XF
authors.lastname: Xing
authors.forename: Hong
authors.initials: H
authors.lastname: DU
authors.forename: Ying
authors.initials: Y
authors.lastname: Hu
authors.forename: Ying-ai
authors.initials: YA
authors.lastname: Li
authors.forename: Yong-ning
authors.initials: YN
authors.lastname: Jia
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.forename: Biao
authors.initials: B
authors.lastname: Fan
authors.forename: Jia-fu
authors.initials: JF
authors.lastname: Ji
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C074601:CA 242 antigen; D018395:CA-19-9 Antigen; C083825:CA-72-4 antigen; D002272:Carcinoembryonic Antigen